Behavioral Health Central to relaunch Web portal
CONSHOHOCKEN, Pa. In an effort to bring together clinicians, patients, payers, executives and administrators on one central Web portal, Behavioral Health Central is relaunching the www.BehavioralHealthCentral.com site.
The new Web portal provides industry and clinical news, resources and tools, and social networking capabilities designed to bring together all of the major stakeholders in behavioral healthcare.
“This new genesis of our site brings everyone to the table so they all have access to similar resources and information,” stated Jim Miller, president of BHC. “It’s a recognition that, in the end, we’re all striving for the same thing — better treatment pathways, leading to improved outcomes for patients.”
Another key feature of the new site is the addition of nationwide directories that allow professionals and consumers to quickly locate treatment facilities, therapists, vendors, drug information, association lists and more.
Teva receives FDA approval for colon cancer generic
JERUSALEM The Food and Drug Administration has approved a generic version of a colon cancer treatment.
Teva Pharmaceutical Industries announced last week the approval and launch of oxaliplatin, an injectable drug, in the 50 mg per 10 milliliter and 100 mg per 20 milliliter strengths. The drug is a generic version of Debiopharm’s and Sanofi-Aventis’ Eloxatin and is approved as an adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and treatment of advanced colorectal cancer.
In June, the U.S. District Court for the District of New Jersey ruled in Teva’s favor, finding that Teva did not infringe U.S. Patent No. 5,338,874, Debiopharm’s patent on Eloxatin. Sanofi and Debiopharm have appealed the decision, and Sanofi has sued the FDA seeking to rescind all approvals of generic oxaliplatin pending resolution of the appeal.
Eloxatin had sales of $1.3 billion in the United States last year, according to IMS Health data.
NACDS president, CEO Anderson joins Rep. Loebsack for pharmacy tours
IOWA CITY, Iowa The head of the largest organization representing the country’s retail pharmacy chains recently went on a short tour in the heartland.
The National Association of Chain Drug Stores announced Monday that president and CEO Steven Anderson accompanied Rep. Dave Loebsack, D-Iowa, in visiting an Iowa City, Iowa, Hartig Drug and a Mount Vernon, Iowa, Shepley Pharmacy in an effort to demonstrate pharmacy’s role in the healthcare system. Anderson is an alumnus of Mount Vernon’s Cornell College and serves on its board of trustees.
“It is my sincere honor to return to Iowa for this important healthcare event,” Anderson said in a statement. “These pharmacy tours will help to raise awareness of the vital role of pharmacy in fostering access to care, reducing healthcare costs and improving patient health and healthcare quality, and we appreciate Rep. Loebsack’s leadership and energetic participating.”
The tours followed the NACDS’ recent Pharmacy and Technology Conference in Boston and RxIMPACT, an advocacy program on Capitol Hill.